Skip to main content
. Author manuscript; available in PMC: 2016 Jan 26.
Published in final edited form as: Cancer Discov. 2015 Apr 20;5(5):475–487. doi: 10.1158/2159-8290.CD-15-0011

Figure 3. Strategies for enhancing the pro-apoptotic activity of BIM.

Figure 3

Demethylating agents or histone deacetylase (HDAC) inhibitors may overcome epigenetic reppression of BIM transcription, whereas MEK inhibitors (e.g. trametinib) decrease BIM degradation—all leading to increased cellular BIM protein levels and increased activation of BAX. BCL-2/BCL-XL inhibitors (e.g. navitoclax) block the ability for anti-apoptotic BCL-2 family members like BCL-2 and BCL-XL to neutralize BIM.